Search Page

1

Cite

Share

Fenebrutinib in H₁ antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.

Metz M, Sussman G, Gagnon R, Staubach P, Tanus T, Yang WH, Lim JJ, Clarke HJ, Galanter J, Chinn LW, Chu T, Teterina A, Burgess T, Haddon DJ, Lu TT, Maurer M. Metz M, et al. Among authors: chinn lw. Nat Med. 2021 Nov;27(11):1961-1969. doi: 10.1038/s41591-021-01537-w. Epub 2021 Nov 8. Nat Med. 2021. PMID: 34750553 Free PMC article. Clinical Trial.

Cite

Share

2

Cite

Share

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).

Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, Rae J, Toth B, Ramamoorthi N, Hackney JA, Berman A, Damjanov N, Fedkov D, Jeka S, Chinn LW, Townsend MJ, Morimoto AM, Genovese MC. Cohen S, et al. Among authors: chinn lw. Arthritis Rheumatol. 2020 Apr 9;72(9):1435-46. doi: 10.1002/art.41275. Online ahead of print. Arthritis Rheumatol. 2020. PMID: 32270926 Free PMC article.

Cite

Share

3

Cite

Share

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.

Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, McGregor A, Toth B, Rae J, Hwang O, Desai R, Lokku A, Ramamoorthi N, Hackney JA, Miranda P, de Souza VA, Jaller-Raad JJ, Maura Fernandes A, Garcia Salinas R, Chinn LW, Townsend MJ, Morimoto AM, Tuckwell K. Isenberg D, et al. Among authors: chinn lw. Arthritis Rheumatol. 2021 Oct;73(10):1835-1846. doi: 10.1002/art.41811. Epub 2021 Aug 24. Arthritis Rheumatol. 2021. PMID: 34042314 Clinical Trial.

Cite

Share

4

Cite

Share

ABCB1 pharmacogenetics: progress, pitfalls, and promise.

Chinn LW, Kroetz DL. Chinn LW, et al. Clin Pharmacol Ther. 2007 Feb;81(2):265-9. doi: 10.1038/sj.clpt.6100052. Clin Pharmacol Ther. 2007. PMID: 17259950 Review.

Cite

Share

5

Cite

Share

Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.

Chen Y, Ma F, Jones NS, Yoshida K, Chiang PC, Durk MR, Wright MR, Jin JY, Chinn LW. Chen Y, et al. Among authors: chinn lw. CPT Pharmacometrics Syst Pharmacol. 2020 Jun;9(6):332-341. doi: 10.1002/psp4.12515. Epub 2020 May 29. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32383787 Free PMC article.

Cite

Share

6

Cite

Share

Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study.

Durk MR, Jones NS, Liu J, Nagapudi K, Mao C, Plise EG, Wong S, Chen JZ, Chen Y, Chinn LW, Chiang PC. Durk MR, et al. Among authors: chinn lw. Clin Pharmacol Ther. 2020 Dec;108(6):1224-1232. doi: 10.1002/cpt.1943. Epub 2020 Jul 18. Clin Pharmacol Ther. 2020. PMID: 32535897 Free PMC article.

Cite

Share

7

Cite

Share

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.

Baruch A, Wong C, Chinn LW, Vaze A, Sonoda J, Gelzleichter T, Chen S, Lewin-Koh N, Morrow L, Dheerendra S, Boismenu R, Gutierrez J, Wakshull E, Wilson ME, Arora PS. Baruch A, et al. Among authors: chinn lw. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28992-29000. doi: 10.1073/pnas.2012073117. Epub 2020 Nov 2. Proc Natl Acad Sci U S A. 2020. PMID: 33139537 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.

Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW. Jones NS, et al. Among authors: chinn lw. Clin Pharmacol Ther. 2020 Jan;107(1):269-277. doi: 10.1002/cpt.1599. Epub 2019 Sep 16. Clin Pharmacol Ther. 2020. PMID: 31376152 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.

Jones NS, Winter H, Katsumoto TR, Florero M, Murray E, Walker H, Singh N, Chinn LW. Jones NS, et al. Among authors: chinn lw. J Pharmacol Exp Ther. 2019 Oct;371(1):202-207. doi: 10.1124/jpet.119.257089. Epub 2019 Aug 1. J Pharmacol Exp Ther. 2019. PMID: 31371481 Clinical Trial.

Cite

Share

10

Cite

Share

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Hodges LM, et al. Among authors: chinn lw. Pharmacogenet Genomics. 2011 Mar;21(3):152-61. doi: 10.1097/FPC.0b013e3283385a1c. Pharmacogenet Genomics. 2011. PMID: 20216335 Free PMC article. No abstract available.

Cite

Share